Investor Relations

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 4:00 PM ET on Aug 29, 2014
Last Price Change Open Day High 52-Week High
15.59
0.05  up   (0.322%) 15.58 15.91 19.55
Volume Previous Close Day Low 52-Week Low
8,100 15.54 15.58 10.90

View all »   RSSRecent Releases

Aug 12, 2014
Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Second Quarter 2014 Financial Results

Aug 5, 2014
Esperion Therapeutics to Provide Second Quarter 2014 Results